SanBio reports Q1 loss amid AKUUGO® preparations, expenses

SanBio Company Limited (TSE:4592) announced a net loss attributable to owners of parent of ¥1,531 million for the three months ended April 30, 2025. This compares to a net loss of ¥144 million for the same period last year. The results were primarily impacted by ¥723 million in research and development expenses, mainly tied to securing partial approval changes for AKUUGO® (SB623), its regenerative medicine product targeting chronic motor paralysis resulting from traumatic brain injury and ¥711 million in foreign exchange losses. Operating loss totaled ¥1,007 million, and ordinary loss was ¥1,750 million.